| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Internal Medicine and Orthopedics (R.M.) and the Clinical Research Center University of Iowa, Iowa City, IA 52242
Address all correspondence and requests for reprints to: Janet A. Schlechte, M.D., Clinical Research Center, University of Iowa Hospital, Iowa City, Iowa 52242.
To determine whether decreased bone density in patients with PRL-secreting pituitary tumors is specifically related to hyperprolactinemia or is a consequence of disordered pituitary-gonadal function common to all amenorrheic states, we measured the bone mineral content of the radius by photon absorptiometry in normal subjects, in women with amenorrhea and normal serum PRL levels, and in women with PRL-secreting pituitary tumors. The women did not differ significantly in mean age, height, weight, or serum calcium, phosphorous, gonadotropin, testosterone, vitamin D, or PTH concentrations, and all had normal renal and thyroid function.
The bone mineral content in women with amenorrhea and normal serum PRL levels (0.91 ± 0.02 g/cm) was not significantly different from that in control subjects (0.88 ± 0.01 g/cm). Patients with PRL-secreting tumors studied 2–5 yr after transsphenoidal surgery had significantly diminished bone mineral content whether they were cured (0.82 ± 0.02 g/cm) or had persistent amenorrhea and hyperprolactinemia (0.81 ± 0.02 g/cm). Serum estradiol concentrations did not differ significantly in the four groups, and there was no correlation between estradiol concentration and bone mineral content or between PRL concentration and bone mineral content in the amenorrheic women.
The presence of decreased bone mineral content in hyperprolactinemic patients suggests that PRL may have a direct effect on bone and may be another indication for early treatment of PRL-secreting pituitary tumors. (J Clin Endocrinol Metab 56: 1120, 1983)
* Presented in part at the 64th Annual Meeting of The Endocrine Society, San Francisco, CA, June 1982. This work was supported by Grants RR-59 and HD-13136, from the NIH.
Received October 4, 1982.
This article has been cited by other articles:
![]() |
A. M. Meaney, S. Smith, O. D. Howes, M. O'brien, R. M. Murray, and V. O'keane Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia The British Journal of Psychiatry, June 1, 2004; 184(6): 503 - 508. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Chowanadisai, S. L. Kelleher, and B. Lonnerdal Maternal Zinc Deficiency Raises Plasma Prolactin Levels in Lactating Rats J. Nutr., June 1, 2004; 134(6): 1314 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Coss, L. Yang, C. B. Kuo, X. Xu, R. A. Luben, and A. M. Walker Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1216 - E1225. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Fahy, M.I. Hopton, M. Hartog, C.H. Bolton, and M.G.R. Hull The lipoprotein profile of women with hyperprolactinaemic amenorrhoea Hum. Reprod., February 1, 1999; 14(2): 285 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M. L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, and G. Lombardi Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 807 - 813. [Abstract] [Full Text] |
||||
![]() |
M. Sowers, G. Corton, B. Shapiro, M. L. Jannausch, M. Crutchfield, M. L. Smith, J. F. Randolph, and B. Hollis Changes in Bone Density With Lactation JAMA, June 23, 1993; 269(24): 3130 - 3135. [Abstract] [PDF] |
||||
![]() |
S. L. Greenspan, D. S. Oppenheim, and A. Klibanski Importance of Gonadal Steroids to Bone Mass in Men with Hyperprolactinemic Hypogonadism Ann Intern Med, April 1, 1989; 110(7): 526 - 531. [Abstract] [PDF] |
||||
![]() |
S. D. Cook, A. F. Harding, K. A. Thomas, E. L. Morgan, K. M. Schnurpfeil, and R. J. Haddad JR Trabecular bone density and menstrual function in women runners Am. J. Sports Med., September 1, 1987; 15(5): 503 - 507. [Abstract] [PDF] |
||||
![]() |
J. S. FINKELSTEIN, A. KLIBANSKI, R. M. NEER, S. L. GREENSPAN, D. I. ROSENTHAL, and W. F. CROWLEY Jr Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism Ann Intern Med, March 1, 1987; 106(3): 354 - 361. [Abstract] [PDF] |
||||
![]() |
J. A. JACKSON, M. KLEEREKOPER, and A. M. PARFITT Symptomatic Osteoporosis in a Man with Hyperprolactinemic Hypogonadism Ann Intern Med, October 1, 1986; 105(4): 543 - 545. [Abstract] [PDF] |
||||
![]() |
B. L. Drinkwater, K. Nilson, S. Ott, and C. H. Chesnut III Bone Mineral Density After Resumption of Menses in Amenorrheic Athletes JAMA, July 18, 1986; 256(3): 380 - 382. [Abstract] [PDF] |
||||
![]() |
S. L. GREENSPAN, R. M. NEER, E. C. RIDGWAY, and A. KLIBANSKI Osteoporosis in Men with Hyperprolactinemic Hypogonadism Ann Intern Med, June 1, 1986; 104(6): 777 - 782. [Abstract] [PDF] |
||||
![]() |
H. HEATH III Athletic Women, Amenorrhea, and Skeletal Integrity Ann Intern Med, February 1, 1985; 102(2): 258 - 260. [Abstract] [PDF] |
||||
![]() |
J. S. LINDBERG, W. B. FEARS, M. M. HUNT, M. R. POWELL, B. DANIEL, and C. E. WADE Exercise-Induced Amenorrhea and Bone Density Ann Intern Med, November 1, 1984; 101(5): 647 - 648. [Abstract] [PDF] |
||||
![]() |
C. E. Cann, M. C. Martin, H. K. Genant, and R. B. Jaffe Decreased Spinal Mineral Content in Amenorrheic Women JAMA, February 3, 1984; 251(5): 626 - 629. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |